Mimi I. Hu, M.D.

Peer-Reviewed Articles

1. Sarvestani AL, Lambdin J, Hu M, Cabanillas M, Waguespack SG, Hernandez JM, Zafereo ME. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol 31(4):2202-2203, 2024. e-Pub 2024. PMID: 38245643.
2. Hamidi S, Hu MI. RET Kinase Inhibitors for the Treatment of RET-Altered Thyroid Cancers: Current Knowledge and Future Directions. Ann Endocrinol (Paris) 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
3. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier N, Brown S, Holla VR, Dadu R, Busaidy N, Sherman SI, Cabanillas M, Waguespack SG, Zafereo ME, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness. J Endocr Soc 8(6):bvae048, 2024. e-Pub 2024. PMID: 38660141.
4. Hensley SG, Hu MI, Bassett RL, Ying AK, Zafereo ME, Perrier ND, Busaidy NL, Hyde SM, Grubbs EG, Waguespack SG. Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-term Outcomes in 144 Patients Over Six Decades. J Clin Endocrinol Metab. e-Pub 2024. PMID: 38441533.
5. Hu MI*, Subbiah V*, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/metastatic RET-altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid 34(1):26-40, 2024. e-Pub 2023. PMID: 38009200.
6. Alsharif O, Panella T, Nodit L, Hu MI. ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma. Thyroid 33(6):774-776, 2023. e-Pub 2023. PMID: 36960705.
7. Hamidi S, Hofmann MC, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14:1176731, 2023. e-Pub 2023. PMID: 37435488.
8. El-Hajj Fuleihan G, Clines GA, Hu MI, Marcocci C, Murad MH, Piggott T, Van Poznak C, Wu JY, Drake MT. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 108(3):507-528, 2023. PMID: 36545746.
9. Contrera KJ, Gule-Monroe MK, Hu MI, Cabanillas ME, Busaidy NL, Dadu R, Waguespack SG, Wang JR, Maniakas A, Lai SY, Diersing J, Kwon M, Grubbs EG, Subbiah V, Williams MD, Zafereo ME. Neoadjuvant Selective RET Inhibitor for Medullary Thyroid Cancer: A Case Series. Thyroid 33(1):129-132, 2023. e-Pub 2022. PMID: 36503246.
10. Wirth LJ, Brose MS, Elisei R, Capdevila J, Hoff AO, Hu MI, Tahara M, Robinson B, Gao M, Xia M, Maeda P, Sherman E. LIBRETTO-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naive RET-mutant Medullary Thyroid Cancer. Future Oncol 18(28):3143-3150, 2022. e-Pub 2022. PMID: 35969032.
11. Vodopivec DM, Hu MI. RET kinase inhibitors for RET-altered thyroid cancers. Ther Adv Med Oncol 14:17588359221101691, 2022. e-Pub 2022. PMID: 35756966.
12. Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the Jaw Risk Factors in Bisphosphonate Treated Patients with Metastatic Cancer. Oral Dis 28(1):193-201, 2022. e-Pub 2021. PMID: 33274559.
13. Hu MI, Subbiah V, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for Patients with Advanced or Metastatic RET-Altered Thyroid Cancer: A Single-Arm, Open-Label, Registrational, Phase 1/2 Study (ARROW). Lancet Diabetes Endocrinol 9(8):491-501, 2021. e-Pub 2021. PMID: 34118198.
14. Hu MI, Waguespack SG, Dosiou C, Ladenson PW, Livhits MJ, Wirth LJ, Sadow PM, Krane JF, Stack BC, Zafereo ME, Ali SZ, Weitzman SP, Hao Y, Babiarz JE, Kennedy GC, Kloos RT. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. J Clin Endocrinol Metab 106(8):2198-2207, 2021. e-Pub 2021. PMID: 34009369.
15. Nguyen H, Shah K, Waguespack SG, Hu MI, Habra MA, Cabanillas ME, Busaidy NL, Bassett R, Zhou S, Iyer PC, Simmons G, Kaya D, Pitteloud M, Subudhi SK, Diab A, Dadu R. Immune Checkpoint Inhibitor Related Hypophysitis: Diagnostic Criteria and Recovery Patterns. Endocr Relat Cancer 28(7):419-31, 2021. e-Pub 2021. PMID: 33890870.
16. Jozaghi Y, Zafereo M, Williams MD, Gule-Monroe MK, Wang J, Grubbs EG, Vaporciyan A, Hu MI, Busaidy N, Dadu R, Waguespack SG, Subbiah V, Cabanillas M. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck 43(1):E7-E12, 2021. e-Pub 2020. PMID: 33169506.
17. Subbiah V, Shen T, Terzyan SS, Liu X, Hu X, Patel KP, Hu M, Cabanillas M, Behrang A, Meri-Bernstam F, Vo PTT, Mooers BHM, Wu J. Structural Basis of Acquired Resistance to Selpercatinib and Pralsetinib Mediated by Non-Gatekeeper RET Mutations. Ann Onc, 2020. e-Pub 2020.
18. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(5):e000799, 2020. PMID: 33097651.
19. Dadu R, Bagheri-Yarmand R, Ringel MD, Grubbs EG, Zafereo M, Cote G, Gagel RF, Robinson BG, Shaw KR, Hu MI. HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocrine-Related Cancer 27(8):T27-T39, 2020. e-Pub 2020. PMID: 32580150.
20. Krane JF, Cibas ES, Endo M, Marqusee E, Hu MI, Nasr CE, Waguespack SG, Wirth LJ, Kloos RT. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision‐making from a fine‐needle aspiration sample. Cancer Cytopathology 128(7):452-9, 2020.
21. Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine Surgery in the Coronavirus Disease 2019 Pandemic: Surgical Triage Guidelines. Head and Neck 42(6):1325-8, 2020. e-Pub 2020.
22. Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167(1):80-86, 2020. e-Pub 2019. PMID: 31648931.
23. Brown SJ, Waguespack SG, Chuang HH, Murphy WA, Hu MI. Detecting the Undetectable. Clinical Thyroidology 32(1):39-42, 2020.
24. Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
25. Doan HQ, Hu MI, Goldstein J, Piha-Paul SA, Subbiah V, Patel AB. Vandetanib photoinduced cutaneous toxicities. Cutis 103(5):E24-E29, 2019. PMID: 31233590.
26. Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L, Krajewska J, Weiss R, Gagel RF. Safety and efficacy of two starting doses of vandetanib in patients with progressive or symptomatic medullary thyroid cancer. Endocrine Related Cancer 26(2):241-50, 2019. PMID: 30557850.
27. Iyer PC, Cabanillas ME, Waguespack SG, Hu MI, Thosani S, Lavis VR, Busaidy NL, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 28(10):1243-1251, 2018. e-Pub 2018. PMID: 30132401.
28. Vodopivec DM, Silva AM, Garcia-Banigan C, Christakis I, Stewart A, Schwarz K, Hussey CS, Bassett R, Hu MI, Perrier ND. Gender Differences in Bone Mineral Density in Patients with Sporadic Primary Hyperparathyroidism. Endocrinology, Diabetes & Metabolism 1(4):e00037. e-Pub 2018. PMID: 30815565.
29. Zagzag J, Hu MI, Fisher SB, Perrier ND. Hypercalcemia and Cancer: Differential Diagnosis and Treatment. CA Cancer J Clin 68(5):377-386, 2018. e-Pub 2018. PMID: 30240520.
30. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov 8(7):836-849, 2018. e-Pub 2018. PMID: 29657135.
31. Romero Arenas MA, Rich TA, Hyde SM, Busaidy NL, Cote GJ, Hu MI, Gagel RF, Gidley PW, Jimenez C, Kupferman ME, Peterson SK, Sherman SI, Ying A, Bassett RL, Waguespack SG, Perrier ND, Grubbs EG. Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Ann Surg Oncol 25(5):1395-1402, 2018. e-Pub 2018. PMID: 29427212.
32. Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the Lateral Neck Compartment in Patients with Sporadic Medullary Thyroid Cancer. Head Neck 40(1):79-85, 2018. e-Pub 2017. PMID: 29044788.
33. Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients with Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-99, 2017. e-Pub 2017. PMID: 28911154.
34. Long KL, Etzel C, Rich T, Hyde S, Perrier ND, Graham PH, Lee JE, Hu MI, Cote GJ, Gagel R, Grubbs EG. All in the Family? Analyzing the Impact of Family History in Addition to Genotype on Medullary Thyroid Carcinoma Aggressiveness in MEN2A Patients. Fam Cancer 16(2):283-289, 2017. e-Pub 2016. PMID: 27864651.
35. Xu JY, Grubbs EG, Waguespack SG, Jimenez C, Gagel RF, Sosa JA, Sellin RV, Dadu R, Hu MI, Trotter CS, Jackson M, Rich TA, Hyde SM, Sherman SI, Cote GJ. Medullary Thyroid Carcinoma Associated with Germline RET K666N Mutation. Thyroid 26(12):1744-1751, 2016. e-Pub 2016. PMID: 27673361.
36. Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
37. Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):jc20162567, 2016. e-Pub 2016. PMID: 27575943.
38. Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 31(8):1569-76, 2016. e-Pub 2016. PMID: 26896384.
39. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
40. Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2015. PMID: 26206754.
41. Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the natural clay, Calcium Aluminosilicate Anti-Diarrheal (CASAD), in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: a pilot study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
42. Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAF(V600E) -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. e-Pub 2014. PMID: 25353071.
43. Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144-52, 2014. e-Pub 2014. PMID: 24915117.
44. Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M, Jimenez C, Lee JE, Perrier N, Sherman SI, Waguespack SG, Ying A, Grubbs E. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096-106, 2014. e-Pub 2014. PMID: 24617864.
45. Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):jc20133588, 2014. e-Pub 2014. PMID: 24628550.
46. Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, Armstrong PA, Liu P, Duvic M. Vitamin D Deficiency in Mycosis Fungoides and Sézary Syndrome Patients Is Similar to Other Cancer Patients. Clin Lymphoma Myeloma Leuk 14(6):518-524. e-Pub 2014. PMID: 25442486.
47. Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aero-digestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24(5):918-22, 2014. e-Pub 2014. PMID: 24635127.
48. Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
49. Thosani S, Ayala-Ramirez M, Palmer L, Hu MI, Rich T, Gagel RF, Cote G, Waguespack SG, Habra MA, Jimenez C. The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. J Clin Endocrinol Metab 98(11):E1813-9, 2013. e-Pub 2013. PMID: 24030942.
50. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Ying W, Jain RK. Denosumab for Patients With Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. J Natl Cancer Inst 105(18):1417-20, 2013. e-Pub 2013. PMID: 23990665.
51. Chae YK, Hu MI, Katz RL, Chavez-MacGregor M, Haluska P, Meric-Bernstam F, Gonzalez-Angulo AM, Melhem-Bertrandt A. Two birds with one stone: octreotide treatment for acromegaly and breast cancer. J Clin Oncol 31(23):e398-400, 2013. e-Pub 2013. PMID: 23796991.
52. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The non-investigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2012. PMID: 23185034.
53. Rianon N, Alex G, Callender G, Jimenez C, Hu M, Grubbs E, Moreno M, Wathoo C, Petak S, Perrier N. Preoperative serum osteocalcin may predict postoperative elevated parathyroid hormone in patients with primary hyperparathyroidism. World J Surg 36(6):1320-6, 2012. e-Pub 2012. PMID: 22278606.
54. Landry CS, Grubbs EG, Hernandez M, Hu MI, Hansen MO, Lee JE, Perrier ND. Predictable criteria for selective, rather than routine, calcium supplementation following thyroidectomy. Arch Surg 147(4):338-44, 2012. e-Pub 2011. PMID: 22184134.
55. Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center experience. Cancer 117(19):4381-9, 2011. e-Pub 2011. PMID: 21412758.
56. Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G, Habra MA. Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2):189-92, 2011. e-Pub 2010. PMID: 21186952.
57. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 2008. PMID: 18558816.

Invited Articles

1. Cabanillas M, Iyer PC, Hu MI. A Decade of Progress in Targeted Therapy for Advanced Thyroid Cancer: An Overview. Endocrine Practice 29(3):221-227, 2023. PMID: 35756966.
2. Jara MA, Varghese J, Hu MI. Adverse Events Associated with Bone-Directed Therapies in Patients with Cancer. Bone 158:115901, 2022. e-Pub 2021. PMID: 33631354.
3. Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am 50(4):721-728, 2021. PMID: 34774243.
4. Cabanillas ME, Hu MI, Dadu R, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am 29(6):1123-43, 2015. PMID: 26568552.
5. Dadu, R, Hu MI, Grubbs EG, Gagel RF. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res(204):227-49, 2015. PMID: 26494392.
6. Thosani S, Hu MI. Denosumab: a new agent in the management of hypercalcemia of malignancy. Future Oncol 11(21):2865-71, 2015. e-Pub 2015. PMID: 26403973.
7. Cabanillas ME, Hu MI, Jimenez C. Medullary Thyroid Cancer in the Era of Tyrosine Kinase Inhibitors: To Treat or Not to Treat-and With Which Drug-Those Are the Questions. J Clin Endocrinol Metab 99(12):4390-6, 2014. PMID: 25238206.
8. Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endo Onc 1(2):203-16, 2014.
9. Hu MI, Ying AK, Jimenez C. Update on medullary thyroid cancer. Endocrinol Metab Clin North Am 43(2):423-42, 2014. PMID: 24891170.
10. Hu MI, Gagel RF. Multiple endocrine neoplasia type 2. Translational Endocrinology & Metabolism 2(4):45-76, 2011.
11. Hu MI. Updates in the management of medullary thyroid cancer. Clin Adv Hematol Oncol 9(5):1-3, 2011. PMID: 21685868.
12. Khan MI, Waguespack SG, Hu MI. Medical management of postsurgical hypoparathyroidism. Endocr Pract 17 Suppl 1:1-19, 2011. e-Pub 2010. PMID: 21134871.
13. Hoff AO, Toth B, Hu MI, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci 1218(1):47-54, 2011. e-Pub 2010. PMID: 20946574.
14. Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
15. Hu MI, Lu H, Gagel RF. Cancer therapies and bone health. Curr Rheumatol Rep 12(3):177-85, 2010. PMID: 20437119.
16. Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3(2):75-88, 2009. e-Pub 2009. PMID: 19412668.
17. Hu MI, Cote G, Gagel RF. RET gene: a therapeutic target in medullary thyroid carcinoma (within issue on "Recent advances in thyroid cancer"). Current Problems in Surgery 45(3):202-212, 2008.
18. Jiménez C, Hu MI, Gagel RF. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37(2):481-96, 2008. PMID: 18502338.
19. Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporos Rep 5(4):170-8, 2007. PMID: 18430392.

Manuals, Teaching Aids, Other Teaching Publications

1. Tannock LR, Boelaert K, Carranza Leon BG, Clement S, Dahir KM, Donner TW, Freel M, Hu M, Irwig MS, Jonklaas J, Magill S, Reddy D, Salvatori R, Subramanian S, Vaidya A, Welt C. ESAP 2018: Endocrine Self-Assessment Program. Endocrine Society: Washington, DC, 2018.
2. Tannock LR, Boelaert K, Collazo-Clavell ML, Dahir KM, Dalkin AC, Donner TW, Freel M, Green J, Hu M, Irwig MS, Jonklaas J, Magill S, Mather K, Subramanian S, Tritos NA, Welt C. ESAP 2017: Endocrine Self-Assessment Program. Endocrine Society: Washington, DC, 2017.

Other Articles

1. Hu MI, Cabanillas ME, Grubbs EG Medullary Thyroid Cancer and Its Primary Treatment - Expert Videos. PracticeUpdate, 2017.

Editorials

1. Hu MI, Cote GJ. Medullary thyroid carcinoma: who's on first?. Thyroid 22(5):451-3, 2012. PMID: 22545752.

Abstracts

1. Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Thyroid 32(S1):P-1-A-188, 2022.
2. Shirali AS, Hu MI, Chiang YJ, Graham PH, Fisher SB, Sosa JA, Perrier ND, Brown S, Subbiah V, Holla VR, Dadu R, Busaidy NL, Sherman SI, Cabanillas ME, Waguespack SG, Zafereo M, Grubbs EG. Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Evaluating the Relationship Between Somatic Alteration Profile and Disease Aggressiveness. Thyroid 32(S1):P-1-A-188, 2022.
3. Hu MI, Subbiah V, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth LJ, Garralda E, Adkins D, Godbert Y, Ahn MJ, Cassier P, Cho BC, Lin CC, Barata T, Zalutskaya A, Scalori A, Brose MS. Updated ARROW Data: Pralsetinib in Patients with Advanced or Metastatic RET-Altered Thyroid Cancer. Ann Oncol 33(suppl 7):S750-Ss757, 2022.
4. Hu MI, Subbiah V, Wirth L, Schuler M, Mansfield AS, Brose MS, Curigliano G, Leboulleux S, Zhu VW, Keam B, Matos I, Lin CC, Adkins D, Baik CS, Lopes G, Godbert Y, Sarker D, Zhang H, Turner CD, Taylor MH. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer. Ann Onc 31(suppl_4):S1026-S1033, 2020.
5. Brown SJ, Gruschjus SK, Waguespack SG, Dadu R, Zafereo M, Cabanillas ME, Grubbs EG, Sherman SI, Hu MI. RAS-mutated sporadic medullary thyroid cancer: A single-center experience. J Clin Oncol 38(suppl; abstr 6584), 2020.
6. Subbiah V, Hu MI, Gainor JF, Mansfield AS, Alonso G, Taylor MH, Zhu VW, Lopez PG, Amatu A, Loebele RC, Cassier PA, Keam B, Schuler MH, Zhang H, Clifford C, Palmer M, Green J, Turner CJ. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 38(suppl; abstr 109), 2020.
7. Gammons S, Hu MI, Zafereo ME, Busaidy NL, Perrier ND, Bassett RL, Hyde SM, Grubbs EG, Waguespack SG. Sporadic MTC in Children: Characterization of a Rare Disease. J Endocrine Society 4(Supplement_1):MON-LB015, 2020.
8. Brown S, Waguespack S, Chuang H, Murphy W, Hu MI. Radiologic Response by 68Gallium DOTATATE PET/CT in Patients with Medullary Thyroid Carcinoma on Systemic Therapy. Thyroid 29(S1), 2019.
9. Taylor MH, Gainor JF, Hu MI, Zhu V, Lopes G, Leboulleux S, Brose MS, Schuler M, Bowles DW, Kim DW, Baik C, Garralda E, Lin CC, Adkins D, Sarker D, Curigliano G, Zhang H, Clifford C, Turner CD, Subbiah V. Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers. J Clin Oncol 37(suppl):abstr 6018, 2019.
10. Cabanillas ME, Busaidy NL, Zafereo M, Waguespack SG, Hu MI, Hofmann MC, Sturgis E, Sherman SI. Neoadjuvant vemurafenib in patients with locally advanced papillary thyroid cancer (PTC). European Thyroid Journal 6(suppl 1):23-118, 2017.
11. Pena I, Grubbs EG, Kanthasamy KA, Lee JE, Hu MI, Cote GJ, Fellman BM, Li Y, Clayman GK, Sturgis EM, Zafereo ME. Prognostic Factors in Surgical Patients with Sporadic Medullary Thyroid Cancer. Thyroid 26(S1):#212, 2016.
12. Cote GJ, Evers C, Hu MI, Grubbs EG, Hai T, Houston, MR, Williams M, Duose DY, Mehrotra M, Busaidy N, Waguespack S, Luthra R, Sherman SI. Liquid Biopsy of CFDNA as a Predictor of Survival in Medullary Thyroid Carcinoma Patients with Somatic RET M918T Mutations. Thyroid 26(S1):#74, 2016.
13. Xu JY, Milton D, Rao S, Jimenez C, Habra M, Waguespack S, Ying A, Cabanillas M, Cote G, Dadu R, Grubbs E, Weitzman S, Busaidy N, Gagel R, Sellin R, Sherman SI, Hu MI. Medullary Thyroid Cancer with Bone Metastases and the Effect of Antiresorptive Agents on Skeletal Related Events: Experience at MD Anderson Cancer Center. Endocrine Reviews 37(2), 2016.
14. Weitzman SP, Waguespack SG, Ying AK, Hu MI, Cabanillas ME. Pain may represent treatment response to targeted therapy in patients with thyroid cancer. Thyroid 25(suppl 1). e-Pub 2015.
15. Velasco G, Hu MI, Jimenez C, Eapen G, Mulanovich VE, Cabanillas ME. Fungal infections mimicking metastatic differentiated thyroid cancer. Endocrine Practice, 2015.
16. Stewart A, Williams M, Hu MI, Feng L, Lee J, Perrier N, Cabanillas M, Cote G, Grubbs EG. The role of somatic RET and RAS mutation in predicting outcome in sporadic medullary thyroid carcinoma. Proceedings for 36th Annual Meeting for the American Association of Endocrine Surgeons, 2015.
17. Weitzman SP, Reicher KT, Dadu R, Hu MI, Jimenez C, Gardner C, Qayyum A, Hernandez M, Cabanillas ME. Salvage therapy: when a tyrosine kinase inhibitor fails in advanced medullary thyroid cancer. Endocrine Reviews. e-Pub 2015.
18. Patham B, Miller E, Murphy WA, Hu MI. Tenofovir-related hypophosphatemic osteomalacia and multiple fractures mimicking metastatic bone disease in a patient with hepatocellular carcinoma. Endocrine Reviews. e-Pub 2015.
19. Pitteloud MJ, Dadu R, Cabanillas ME, Shah K, Hu MI, Habra MA, Waguespack SG. Hypophysitis in the age of cancer immunotherapy: experience in a large cancer center. Endocrine Reviews. e-Pub 2015.
20. Trotter C, Farhood Z, Hu MI, Cabanillas M, Jackson M, Rich T, Graham P, Lee J, Perrier N, Grubbs EG. Accuracy of data collected in a hereditary cancer registry, the MEN2 experience. 10th Annual Academic Surgical Congress, 2015.
21. Dadu R, Hu MI, Cleeland CS, Busaidy NL, Habra MA, Waguespack SG, Sherman SI, Ying AK, Fox P, Cabanillas M. The efficacy of the natural clay, CASAD, in reducing medullary thyroid cancer-related diarrhea and its effects on quality of life: A pilot study. Thyroid 24(S1):P166, 2014.
22. Dadu R, Shah K, Bassett RL, Busaidy NL, Waguespack SG, Sherman SI, Habra MA, Jimenez C, Hu MI, Ying AK, Cabanillas ME. Is there an alternative treatment option for patients with advanced papillary thyroid cancer harboring the BRAFV600E mutation. Endocrine Reviews 35(3 Suppl):OR52-4, 2014.
23. Edwards BJ, Lu H, Hu MI, Saraykar S, Bunta A, West DP, Barcenas CH, Gagel RF, Hortobagyi GN, Murphy WA. Risk factors for atypical femur fractures in cancer patients. J Clin Oncol 32(Suppl; abstr e12533), 2014.
24. Xu J, Gagel RF, Hu MI. Denosumab-induced refractory hypocalcemia in a patient with breast cancer and diffuse osteoblastic bone metastases and surgical hypoparathyroidism. AACE Annual Meeting, Las Vegas, NV, 05/2014:Abstract 620. e-Pub 2014.
25. Hu MI, Glezerman I, Leboulleux X, Insogna KL, Gucalp RA, Misiorowski W, Yu BW, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain RK. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). J Clin Oncology 31(suppl; abstr e20512), 2013. e-Pub 2013.
26. Dadu R, Devine C, Hernandez M, Busaidy N, Waguespack S, Ying A, Habra M, Thosani S, Hu M, Cabanillas M. Is second-line targeted therapy beneficial in patients (pts) with differentiated thyroid cancer (DTC) after first-line sorafenib (SOR) failure?. J Clin Oncology 31(suppl; abstr e17016), 2013. e-Pub 2013.
27. Cabanillas ME, Holsinger FC, Sturgis E, Habra M, Davies MA, Munsell M, Busaidy N, Hu M, Sherman SI. Pharmacodynamic study of neoadjuvant vemurafenib (VEM) in patients (pts) with BRAF mutated, locally advanced papillary thyroid cancer (PTC). J Clin Oncology 31(suppl; abstr TPS6100), 2013.

Book Chapters

1. Skefos CM, Waguespack SG, Perrier ND, Hu MI. CDC73-Related Disorders. In: GeneReviews®. University of Washington: Seattle, 2023.
2. Jaber T, Dadu R, Hu MI. Medullary thyroid carcinoma. In: Curr Opin Endocrinol Diabetes Obes. 10th. McGraw-Hill, 744-65, 2021.
3. Dadu R, Hu MI. Medical Treatment Decision-Making for Advanced Medullary Thyroid Cancer. In: Thyroid Cancer: A Case-Based Approach. 2nd. Springer Nature, 2020.
4. Hu MI, Grubbs EG, Sosa JA. Medullary Thyroid Carcinoma. In: Medical Management of Thyroid Disease. 3rd. CRC Press, 225-42, 2019.
5. Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. CDC73-Related Disorders. In: GeneReviews. GeneReviews, 2018.
6. Callejas LP, Ahn P, Holsinger FC, Hu MI. Thyroid and Parathyroid Cancers. In: Cancer Management Handbook. 17th. UBM Medica US: Norwalk, CT, 2016.
7. Dadu R, Gagel RF, Hu MI. Medical treatment decision-making for advanced, progressive medullary thyroid cancer. In: Thyroid Cancer - A Case-Based Textbook. Springer: New York, 365-374, 2015.
8. Waguespack SG, Grubbs EG, Hu MI. Multiple endocrine neoplasia type 2. In: Clinical Genomics: Practical Applications in Adult Patient Care. 1st. McGraw Hill Education, 278-83, 2014.
9. Hu MI, Jimenez C, Busaidy NL, Habra M. Long-term and late endocrine effects of cancer survivorship. In: Cancer Survivorship. 1st. Springer, 2014.
10. Dadu R, Ahn P, Holsinger FC, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 15th. UBM Medica: Connecticut, 2013.
11. Hu MI, Jimenez C, Cote GJ, Gagel RF. Medullary thyroid carcinoma. In: The Thyroid. 10th. Lippincott Williams & Wilkins: Philadephia, PA, 744-65, 2012.
12. Thosani S, Ahn P, Hu MI. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 14th. CMP Medica, 2012.
13. Rich TA, Hu MI, Martin JW, Perrier ND, Waguespack SG. CDC73-related disorders. In: GeneReviews at GeneTests, 2012.
14. Alford E, Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 13th Edition. CMPMedica, 2011.
15. Hu MI, Ahn P, Lamont JP. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 12th Edition. CMPMedica, 51-70, 2010.
16. Hu M, Gagel RF. Multiple endocrine neoplasia type 2. In: Endocrinology. 6th edition. Saunders, 2010.
17. Hu MI, Yeung SJ, Gagel RF.. Endocrine paraneoplastic syndromes. In: Internal Medicine Care of Cancer Patients. BC Decker Inc; the Holland-Frei Series: Ontario, 2009.
18. Hu MI, Sherman SI. Endocrine complications of head and neck surgery. In: Complications in Head and Neck Surgery, 2nd edition, 2009.
19. Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancers. In: Cancer Management: A Multidisciplinary Approach. 11th Edition. CMPMedica, 2009.
20. Hu MI, Gagel RF. Calcitonin gene family of peptides. In: Principles of Bone Biology, 3rd edition, 2008.